25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ACRV (Acrivon) Stock Analysis
Buy, Hold or Sell?

Let's analyze Acrivon together

I guess you are interested in Acrivon Therapeutics, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Acrivon’s Financial Insights
  • 📈 Technical Analysis (TA) – Acrivon’s Price Targets

I'm going to help you getting a better view of Acrivon Therapeutics, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Acrivon Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Acrivon Therapeutics, Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of Acrivon (30 sec.)










1.2. What can you expect buying and holding a share of Acrivon? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.72
Expected worth in 1 year
$1.46
How sure are you?
13.3%

+ What do you gain per year?

Total Gains per Share
$-2.26
Return On Investment
-148.7%

For what price can you sell your share?

Current Price per Share
$1.52
Expected price per share
$1.3 - $4.485
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Acrivon (5 min.)




Live pricePrice per Share (EOD)
$1.52
Intrinsic Value Per Share
$-22.51 - $-26.43
Total Value Per Share
$-18.80 - $-22.71

2.2. Growth of Acrivon (5 min.)




Is Acrivon growing?

Current yearPrevious yearGrowGrow %
How rich?$143m$145.8m$23.4m13.8%

How much money is Acrivon making?

Current yearPrevious yearGrowGrow %
Making money-$21.4m-$17.2m-$4.2m-19.7%
Net Profit Margin-673.1%-255.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Acrivon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Acrivon?

Welcome investor! Acrivon's management wants to use your money to grow the business. In return you get a share of Acrivon.

First you should know what it really means to hold a share of Acrivon. And how you can make/lose money.

Speculation

The Price per Share of Acrivon is $1.52. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acrivon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acrivon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.72. Based on the TTM, the Book Value Change Per Share is $-0.57 per quarter. Based on the YOY, the Book Value Change Per Share is $0.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acrivon.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.55-35.9%-0.56-36.9%-0.53-34.8%-0.48-31.7%-0.42-27.7%-0.42-27.7%
Usd Book Value Change Per Share-0.46-30.5%-0.57-37.2%0.3120.3%0.4126.8%0.2516.3%0.2516.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.46-30.5%-0.57-37.2%0.3120.3%0.4126.8%0.2516.3%0.2516.3%
Usd Price Per Share1.19-4.06-6.86-6.74-5.39-5.39-
Price to Earnings Ratio-0.54--1.76--3.35--3.81--3.05--3.05-
Price-to-Total Gains Ratio-2.57--6.71--12.78--13.85--13.85--13.85-
Price to Book Ratio0.32-0.87-1.63-1.44-1.15-1.15-
Price-to-Total Gains Ratio-2.57--6.71--12.78--13.85--13.85--13.85-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.52
Number of shares657
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.570.25
Usd Total Gains Per Share-0.570.25
Gains per Quarter (657 shares)-371.31162.89
Gains per Year (657 shares)-1,485.23651.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1485-14950652642
20-2970-2980013031294
30-4456-4465019551946
40-5941-5950026062598
50-7426-7435032583250
60-8911-8920039093902
70-10397-10405045614554
80-11882-11890052125206
90-13367-13375058645858
100-14852-14860065166510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.015.00.00.0%0.015.00.00.0%0.015.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%2.012.01.013.3%2.012.01.013.3%2.012.01.013.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.015.00.0%0.00.015.00.0%0.00.015.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%2.012.01.013.3%2.012.01.013.3%2.012.01.013.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Acrivon Therapeutics, Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.463-0.565+22%0.309-250%0.407-214%0.248-287%0.248-287%
Book Value Per Share--3.7194.423-16%4.414-16%4.097-9%3.099+20%3.099+20%
Current Ratio--10.30511.194-8%13.463-23%14.517-29%16.521-38%16.521-38%
Debt To Asset Ratio--0.0980.093+5%0.094+4%0.204-52%0.419-77%0.419-77%
Debt To Equity Ratio--0.1090.103+6%0.104+4%0.085+27%0.068+59%0.068+59%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--167646326.610301366991.293-44%348232950.200-52%375925219.815-55%375925219.815-55%375925219.815-55%
Eps---0.546-0.561+3%-0.529-3%-0.482-12%-0.421-23%-0.421-23%
Ev To Ebitda Ratio---1.850-3.230+75%-5.716+209%-5.969+223%-5.969+223%-5.969+223%
Free Cash Flow Per Share---0.445-0.478+7%-0.425-4%-0.399-10%-0.361-19%-0.361-19%
Free Cash Flow To Equity Per Share---0.447-0.495+11%0.412-209%0.145-408%0.286-256%0.286-256%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---26.425----------
Intrinsic Value_10Y_min---22.514----------
Intrinsic Value_1Y_max---1.752----------
Intrinsic Value_1Y_min---1.720----------
Intrinsic Value_3Y_max---5.947----------
Intrinsic Value_3Y_min---5.663----------
Intrinsic Value_5Y_max---10.965----------
Intrinsic Value_5Y_min---10.118----------
Market Cap47812512.000+4%45769326.610155143991.293-70%222488450.200-79%223311201.498-80%178648961.198-74%178648961.198-74%
Net Profit Margin----6.7310%-2.5550%-3.0950%-2.4760%-2.4760%
Operating Margin----7.3570%-2.7940%-3.3830%-2.7070%-2.7070%
Operating Ratio---7.392-100%2.794-100%3.395-100%2.716-100%2.716-100%
Pb Ratio0.409+22%0.3200.866-63%1.627-80%1.443-78%1.154-72%1.154-72%
Pe Ratio-0.696-28%-0.545-1.757+222%-3.351+515%-3.810+600%-3.048+460%-3.048+460%
Price Per Share1.520+22%1.1904.060-71%6.858-83%6.737-82%5.389-78%5.389-78%
Price To Free Cash Flow Ratio-0.855-28%-0.669-2.117+216%-4.351+550%-4.593+587%-3.675+449%-3.675+449%
Price To Total Gains Ratio-3.281-28%-2.569-6.713+161%-12.780+398%-13.847+439%-13.847+439%-13.847+439%
Quick Ratio--17.34419.363-10%23.333-26%24.963-31%23.505-26%23.505-26%
Return On Assets---0.132-0.116-12%-0.113-14%-0.101-24%-0.092-30%-0.092-30%
Return On Equity---0.147-0.128-13%-0.126-14%-0.102-30%-0.082-44%-0.082-44%
Total Gains Per Share---0.463-0.565+22%0.309-250%0.407-214%0.248-287%0.248-287%
Usd Book Value--143037000.000169276250.000-16%145845250.000-2%141249833.333+1%107386933.333+33%107386933.333+33%
Usd Book Value Change Per Share---0.463-0.565+22%0.309-250%0.407-214%0.248-287%0.248-287%
Usd Book Value Per Share--3.7194.423-16%4.414-16%4.097-9%3.099+20%3.099+20%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--167646326.610301366991.293-44%348232950.200-52%375925219.815-55%375925219.815-55%375925219.815-55%
Usd Eps---0.546-0.561+3%-0.529-3%-0.482-12%-0.421-23%-0.421-23%
Usd Free Cash Flow---17103000.000-18298750.000+7%-13815250.000-19%-13801166.667-19%-12340600.000-28%-12340600.000-28%
Usd Free Cash Flow Per Share---0.445-0.478+7%-0.425-4%-0.399-10%-0.361-19%-0.361-19%
Usd Free Cash Flow To Equity Per Share---0.447-0.495+11%0.412-209%0.145-408%0.286-256%0.286-256%
Usd Market Cap47812512.000+4%45769326.610155143991.293-70%222488450.200-79%223311201.498-80%178648961.198-74%178648961.198-74%
Usd Price Per Share1.520+22%1.1904.060-71%6.858-83%6.737-82%5.389-78%5.389-78%
Usd Profit---21006000.000-21489500.000+2%-17250500.000-18%-16393916.667-22%-14272400.000-32%-14272400.000-32%
Usd Revenue---212000.000-100%471000.000-100%227666.667-100%182133.333-100%182133.333-100%
Usd Total Gains Per Share---0.463-0.565+22%0.309-250%0.407-214%0.248-287%0.248-287%
 EOD+5 -3MRQTTM+17 -17YOY+5 -293Y+7 -275Y+9 -2510Y+9 -25

3.3 Fundamental Score

Let's check the fundamental score of Acrivon Therapeutics, Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.696
Price to Book Ratio (EOD)Between0-10.409
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than117.344
Current Ratio (MRQ)Greater than110.305
Debt to Asset Ratio (MRQ)Less than10.098
Debt to Equity Ratio (MRQ)Less than10.109
Return on Equity (MRQ)Greater than0.15-0.147
Return on Assets (MRQ)Greater than0.05-0.132
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Acrivon Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.536
Ma 20Greater thanMa 501.408
Ma 50Greater thanMa 1001.358
Ma 100Greater thanMa 2001.322
OpenGreater thanClose1.550
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2025-09-10 03:14:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Acrivon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-673.1%+673.1%
TTM-673.1%YOY-255.5%-417.6%
TTM-673.1%5Y-247.6%-425.5%
5Y-247.6%10Y-247.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--73.5%+73.5%
TTM-673.1%-154.3%-518.8%
YOY-255.5%-207.9%-47.6%
3Y-309.5%-272.9%-36.6%
5Y-247.6%-345.5%+97.9%
10Y-247.6%-504.5%+256.9%
4.3.1.2. Return on Assets

Shows how efficient Acrivon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • -13.2% Return on Assets means that Acrivon generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is -13.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.2%TTM-11.6%-1.6%
TTM-11.6%YOY-11.3%-0.3%
TTM-11.6%5Y-9.2%-2.4%
5Y-9.2%10Y-9.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-11.8%-1.4%
TTM-11.6%-11.6%0.0%
YOY-11.3%-11.0%-0.3%
3Y-10.1%-11.9%+1.8%
5Y-9.2%-11.5%+2.3%
10Y-9.2%-13.6%+4.4%
4.3.1.3. Return on Equity

Shows how efficient Acrivon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • -14.7% Return on Equity means Acrivon generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is -14.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.7%TTM-12.8%-1.9%
TTM-12.8%YOY-12.6%-0.2%
TTM-12.8%5Y-8.2%-4.7%
5Y-8.2%10Y-8.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.7%-13.7%-1.0%
TTM-12.8%-14.6%+1.8%
YOY-12.6%-15.0%+2.4%
3Y-10.2%-16.4%+6.2%
5Y-8.2%-16.9%+8.7%
10Y-8.2%-19.0%+10.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Acrivon Therapeutics, Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Acrivon is operating .

  • Measures how much profit Acrivon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-735.7%+735.7%
TTM-735.7%YOY-279.4%-456.3%
TTM-735.7%5Y-270.7%-465.0%
5Y-270.7%10Y-270.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--153.1%+153.1%
TTM-735.7%-247.8%-487.9%
YOY-279.4%-244.8%-34.6%
3Y-338.3%-256.2%-82.1%
5Y-270.7%-340.5%+69.8%
10Y-270.7%-503.1%+232.4%
4.3.2.2. Operating Ratio

Measures how efficient Acrivon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM7.392-7.392
TTM7.392YOY2.794+4.599
TTM7.3925Y2.716+4.676
5Y2.71610Y2.7160.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.859-1.859
TTM7.3922.752+4.640
YOY2.7942.941-0.147
3Y3.3953.642-0.247
5Y2.7164.701-1.985
10Y2.7166.681-3.965
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Acrivon Therapeutics, Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Acrivon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.31 means the company has $10.31 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 10.305. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.194. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.305TTM11.194-0.889
TTM11.194YOY13.463-2.269
TTM11.1945Y16.521-5.327
5Y16.52110Y16.5210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.3053.457+6.848
TTM11.1943.689+7.505
YOY13.4634.093+9.370
3Y14.5174.571+9.946
5Y16.5215.722+10.799
10Y16.5216.137+10.384
4.4.3.2. Quick Ratio

Measures if Acrivon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • A Quick Ratio of 17.34 means the company can pay off $17.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 17.344. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 19.363. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ17.344TTM19.363-2.018
TTM19.363YOY23.333-3.971
TTM19.3635Y23.505-4.143
5Y23.50510Y23.5050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.3442.940+14.404
TTM19.3633.288+16.075
YOY23.3333.896+19.437
3Y24.9634.373+20.590
5Y23.5055.800+17.705
10Y23.5056.520+16.985
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Acrivon Therapeutics, Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Acrivon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acrivon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Acrivon assets are financed with 9.8% credit (debt) and the remaining percentage (100% - 9.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.098. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.093. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.098TTM0.093+0.005
TTM0.093YOY0.094-0.001
TTM0.0935Y0.419-0.326
5Y0.41910Y0.4190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0980.339-0.241
TTM0.0930.356-0.263
YOY0.0940.334-0.240
3Y0.2040.344-0.140
5Y0.4190.351+0.068
10Y0.4190.378+0.041
4.5.4.2. Debt to Equity Ratio

Measures if Acrivon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acrivon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.9% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The MRQ is 0.109. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.103. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.109TTM0.103+0.006
TTM0.103YOY0.104-0.002
TTM0.1035Y0.068+0.034
5Y0.06810Y0.0680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1090.393-0.284
TTM0.1030.439-0.336
YOY0.1040.435-0.331
3Y0.0850.462-0.377
5Y0.0680.463-0.395
10Y0.0680.511-0.443
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acrivon generates.

  • Above 15 is considered overpriced but always compare Acrivon to the Biotechnology industry mean.
  • A PE ratio of -0.54 means the investor is paying $-0.54 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The EOD is -0.696. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.545. Based on the earnings, the company is expensive. -2
  • The TTM is -1.757. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.696MRQ-0.545-0.151
MRQ-0.545TTM-1.757+1.212
TTM-1.757YOY-3.351+1.595
TTM-1.7575Y-3.048+1.292
5Y-3.04810Y-3.0480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.696-2.447+1.751
MRQ-0.545-2.328+1.783
TTM-1.757-2.662+0.905
YOY-3.351-3.729+0.378
3Y-3.810-3.747-0.063
5Y-3.048-6.305+3.257
10Y-3.048-6.948+3.900
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The EOD is -0.855. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.669. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.117. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.855MRQ-0.669-0.186
MRQ-0.669TTM-2.117+1.448
TTM-2.117YOY-4.351+2.233
TTM-2.1175Y-3.675+1.557
5Y-3.67510Y-3.6750.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.855-3.310+2.455
MRQ-0.669-2.934+2.265
TTM-2.117-3.859+1.742
YOY-4.351-4.296-0.055
3Y-4.593-5.225+0.632
5Y-3.675-8.425+4.750
10Y-3.675-9.639+5.964
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Acrivon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.32 means the investor is paying $0.32 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Acrivon Therapeutics, Inc. Common Stock:

  • The EOD is 0.409. Based on the equity, the company is cheap. +2
  • The MRQ is 0.320. Based on the equity, the company is cheap. +2
  • The TTM is 0.866. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.409MRQ0.320+0.089
MRQ0.320TTM0.866-0.546
TTM0.866YOY1.627-0.761
TTM0.8665Y1.154-0.289
5Y1.15410Y1.1540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4092.233-1.824
MRQ0.3202.000-1.680
TTM0.8662.205-1.339
YOY1.6272.413-0.786
3Y1.4432.571-1.128
5Y1.1543.756-2.602
10Y1.1544.451-3.297
4.6.2. Total Gains per Share

2.4. Latest News of Acrivon Therapeutics, Inc. Common Stock

Does Acrivon Therapeutics, Inc. Common Stock still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Acrivon Therapeutics, Inc. Common Stock to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-05
23:00
Friday's after hours session: top gainers and losersRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Acrivon Therapeutics, Inc. Common Stock.

4.8.1. Institutions holding Acrivon Therapeutics, Inc. Common Stock

Institutions are holding 56.748% of the shares of Acrivon Therapeutics, Inc. Common Stock.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30RA Capital Management, LLC26.51510.1672834050800
2025-06-30Sands Capital Ventures, LLC6.74790.4974212260500
2025-06-30Citadel Advisors Llc6.0260.0004189551900
2025-03-31BlackRock Inc2.98420938707-6789-0.718
2025-06-30Wellington Management Company LLP2.82340.000288813000
2025-06-30Vanguard Group Inc1.8860593247-81543-12.0842
2025-06-30Jacobs Levy Equity Management, Inc.1.21520.00183822343822340
2025-03-31Geode Capital Management, LLC0.97320.000130611147221.5667
2025-03-31State Street Corp0.73930232551-4050-1.7117
2025-06-30Marshall Wace Asset Management Ltd0.5760.0002181187-269204-59.7712
2025-06-30Two Sigma Investments LLC0.5760.00041811721811720
2025-06-30Squarepoint Ops LLC0.48510.00021526051526050
2025-06-30Goldman Sachs Group Inc0.4452014005582536143.4935
2025-03-31Northern Trust Corp0.34660109025-8298-7.0728
2025-06-30XTX Topco Ltd0.33740.00521061191061190
2025-06-30Charles Schwab Investment Management Inc0.2023063636-47684-42.8351
2025-03-31Renaissance Technologies Corp0.16560.00025210027005.4656
2025-06-30Susquehanna International Group, LLP0.139404386029280200.823
2025-03-31Amvescap Plc.0.1123035315353150
2025-03-31Morgan Stanley - Brokerage Accounts0.1120352214901.4108
Total 53.40820.673316799907+559605+3.3%

4.9.2. Funds holding Acrivon Therapeutics, Inc. Common Stock

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Total Stock Mkt Idx Inv1.28310403608-8821-2.1388
2025-08-29iShares Biotechnology ETF0.40010.0031125846-1106-0.8712
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.38520.0002121158-55207-31.3027
2025-07-31Fidelity Extended Market Index0.23360.000273470-605-0.8167
2025-08-30Schwab US Small-Cap ETF™0.20220.0005636081400.2206
2025-08-29iShares Micro-Cap ETF0.1390.00654371000
2025-06-30Extended Equity Market Fund K0.13280.000341771-834-1.9575
2025-02-28Vifag 2002 SICAV0.11130.27013500000
2025-07-31Fidelity Total Market Index0.079302495800
2025-07-31Fidelity Series Total Market Index0.060701909000
2025-07-31Fidelity Nasdaq Composite Index0.05740.00011805300
2025-06-30Bridgeway Ultra-Small Company Market0.05720.0218000-55000-75.3425
2025-07-31Spartan Extended Market Index Pool F0.0530.0002166786053.7641
2025-08-29iShares Nasdaq US Biotech ETF USD Acc0.05210.003816394-153-0.9246
2025-06-30NT Ext Equity Mkt Idx Fd - L0.04940.00031553100
2025-03-31NT Col R2000 Val Idx Fd -DC -L -TierFour0.04210.00213236-11402-46.2781
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.03910.00021230900
2025-07-31Spartan Total Market Index Pool G0.037901191800
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.03040.00029558-24-0.2505
2024-12-31Vanguard Instl Ttl Stck Mkt Idx Tr0.02040.0001640400
Total 3.46630.30781090300-132407-12.1%

5.3. Insider Transactions

Insiders are holding 20.643% of the shares of Acrivon Therapeutics, Inc. Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-04-30Perceptive Advisors LlcSELL4378811.41
2025-04-28Perceptive Advisors LlcSELL2152831.56
2025-04-25Perceptive Advisors LlcSELL10546691.95
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets158,583
Total Liabilities15,546
Total Stockholder Equity143,037
 As reported
Total Liabilities 15,546
Total Stockholder Equity+ 143,037
Total Assets = 158,583

Assets

Total Assets158,583
Total Current Assets138,412
Long-term Assets20,171
Total Current Assets
Cash And Cash Equivalents 41,895
Short-term Investments 95,528
Other Current Assets 989
Total Current Assets  (as reported)138,412
Total Current Assets  (calculated)138,412
+/-0
Long-term Assets
Property Plant Equipment 8,124
Long Term Investments 10,199
Long-term Assets Other 1,848
Long-term Assets  (as reported)20,171
Long-term Assets  (calculated)20,171
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities13,431
Long-term Liabilities2,115
Total Stockholder Equity143,037
Total Current Liabilities
Short-term Debt 2,296
Accounts payable 1,163
Other Current Liabilities 9,972
Total Current Liabilities  (as reported)13,431
Total Current Liabilities  (calculated)13,431
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt967
Long-term Liabilities  (as reported)2,115
Long-term Liabilities  (calculated)967
+/- 1,148
Total Stockholder Equity
Common Stock31
Retained Earnings -237,662
Accumulated Other Comprehensive Income 106
Other Stockholders Equity 380,562
Total Stockholder Equity (as reported)143,037
Total Stockholder Equity (calculated)143,037
+/-0
Other
Capital Stock31
Cash and Short Term Investments 137,423
Common Stock Shares Outstanding 38,462
Liabilities and Stockholders Equity 158,583
Net Debt -38,632
Net Invested Capital 143,037
Net Working Capital 124,981
Property Plant and Equipment Gross 10,732
Short Long Term Debt Total 3,263



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-03-31
> Total Assets 
0
0
106,587
0
94,996
87,713
181,226
170,197
160,049
151,092
138,265
120,521
230,585
214,684
196,588
176,349
158,583
158,583176,349196,588214,684230,585120,521138,265151,092160,049170,197181,22687,71394,9960106,58700
   > Total Current Assets 
0
100,408
100,408
87,162
87,162
78,672
127,751
123,963
153,282
144,492
129,692
112,143
182,358
188,984
181,629
151,327
138,412
138,412151,327181,629188,984182,358112,143129,692144,492153,282123,963127,75178,67287,16287,162100,408100,4080
       Cash And Cash Equivalents 
0
0
99,603
0
83,861
32,080
29,519
27,489
38,074
29,859
36,015
24,607
46,006
43,415
39,818
39,154
41,895
41,89539,15439,81843,41546,00624,60736,01529,85938,07427,48929,51932,08083,861099,60300
       Short-term Investments 
0
0
0
0
0
44,743
98,232
92,723
112,880
112,231
91,443
85,368
134,531
144,038
139,662
110,481
95,528
95,528110,481139,662144,038134,53185,36891,443112,231112,88092,72398,23244,74300000
       Other Current Assets 
0
0
805
0
3,301
1,849
4,344
3,751
2,328
2,402
2,234
2,168
1,821
1,531
2,149
1,692
989
9891,6922,1491,5311,8212,1682,2342,4022,3283,7514,3441,8493,301080500
   > Long-term Assets 
0
0
6,179
0
7,834
9,041
53,475
46,234
6,767
6,600
8,573
8,378
48,227
25,700
14,959
25,022
20,171
20,17125,02214,95925,70048,2278,3788,5736,6006,76746,23453,4759,0417,83406,17900
       Property Plant Equipment 
0
5,791
5,791
7,222
7,222
7,109
6,862
6,571
6,359
6,189
7,908
7,613
7,443
8,467
8,025
7,982
8,124
8,1247,9828,0258,4677,4437,6137,9086,1896,3596,5716,8627,1097,2227,2225,7915,7910
       Long Term Investments 
0
0
0
0
0
0
41,881
39,275
0
0
0
0
39,895
15,390
5,089
15,195
10,199
10,19915,1955,08915,39039,895000039,27541,881000000
       Other Assets 
0
388
388
612
612
1,932
388
0
408
0
0
0
0
0
0
0
0
0000000040803881,9326126123883880
       Deferred Long Term Asset Charges 
0
0
0
0
0
1,544
0
0
0
0
0
0
0
0
0
0
0
000000000001,54400000
> Total Liabilities 
0
0
130,396
0
131,572
133,329
10,751
9,728
10,865
12,943
17,070
12,542
14,527
17,792
19,802
15,959
15,546
15,54615,95919,80217,79214,52712,54217,07012,94310,8659,72810,751133,329131,5720130,39600
   > Total Current Liabilities 
0
2,914
2,914
4,452
4,452
6,391
6,516
5,682
7,017
9,299
13,303
9,041
11,284
14,819
17,214
13,550
13,431
13,43113,55017,21414,81911,2849,04113,3039,2997,0175,6826,5166,3914,4524,4522,9142,9140
       Short-term Debt 
0
0
664
0
706
717
726
1,480
1,506
1,552
1,754
1,888
1,956
2,080
2,114
2,210
2,296
2,2962,2102,1142,0801,9561,8881,7541,5521,5061,480726717706066400
       Accounts payable 
0
964
964
1,902
1,902
1,976
904
1,374
1,267
1,504
5,048
2,056
1,261
1,506
758
3,691
1,163
1,1633,6917581,5061,2612,0565,0481,5041,2671,3749041,9761,9021,9029649640
       Other Current Liabilities 
0
66
1,220
0
1,844
3,698
4,817
2,828
4,244
6,243
6,501
5,097
8,067
11,233
14,342
7,649
9,972
9,9727,64914,34211,2338,0675,0976,5016,2434,2442,8284,8173,6981,84401,220660
   > Long-term Liabilities 
0
0
127,482
0
127,120
126,938
4,235
4,046
3,848
3,644
3,767
3,501
3,243
2,973
2,588
2,409
2,115
2,1152,4092,5882,9733,2433,5013,7673,6443,8484,0464,235126,938127,1200127,48200
       Deferred Long Term Asset Charges 
0
0
0
0
0
1,544
0
0
0
0
0
0
0
0
0
0
0
000000000001,54400000
       Warrants
0
0
0
0
0
245,036
0
0
0
0
0
0
0
0
0
0
0
00000000000245,03600000
       Deferred Long Term Liability 
0
0
0
224
224
1,544
0
0
0
0
0
0
0
0
0
0
0
000000000001,544224224000
> Total Stockholder Equity
0
0
-23,809
0
-36,576
-45,616
170,475
160,469
149,184
138,149
121,195
107,979
216,058
196,892
176,786
160,390
143,037
143,037160,390176,786196,892216,058107,979121,195138,149149,184160,469170,475-45,616-36,5760-23,80900
   Common Stock
0
2
2
4
2
2
22
22
22
22
23
23
31
31
31
31
31
3131313131232322222222224220
   Retained Earnings Total Equity000000000-68,788-56,032-47,10300000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-133
-95
9
-427
-302
-83
-70
-19
782
447
283
106
106283447782-19-70-83-302-4279-95-13300000
   Capital Surplus 
0
0
0
0
0
1,618
226,580
229,226
0
0
0
0
0
0
0
0
0
000000000229,226226,5801,61800000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
0
0
1,054
0
1,327
-120,900
226,580
229,226
232,291
235,597
237,675
240,932
367,750
370,224
373,284
376,732
380,562
380,562376,732373,284370,224367,750240,932237,675235,597232,291229,226226,580-120,9001,32701,05400



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,006
Gross Profit-1,006-1,006
 
Operating Income (+$)
Gross Profit-1,006
Operating Expense-88,193
Operating Income-89,199-89,199
 
Operating Expense (+$)
Research Development63,992
Selling General Administrative25,207
Selling And Marketing Expenses0
Operating Expense88,19389,199
 
Net Interest Income (+$)
Interest Income9,201
Interest Expense-0
Other Finance Cost-0
Net Interest Income9,201
 
Pretax Income (+$)
Operating Income-89,199
Net Interest Income9,201
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-80,556-97,842
EBIT - interestExpense = -80,556
-80,556
-80,556
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-80,556-80,556
Earnings Before Interest and Taxes (EBITDA)-79,550
 
After tax Income (+$)
Income Before Tax-80,556
Tax Provision-0
Net Income From Continuing Ops-80,556-80,556
Net Income-80,556
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses89,199
Total Other Income/Expenses Net8,643-9,201
 

Technical Analysis of Acrivon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acrivon. The general trend of Acrivon is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acrivon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Acrivon Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Acrivon Therapeutics, Inc. Common Stock.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.19 < 3.19 < 4.485.

The bearish price targets are: 1.5 > 1.435 > 1.3.

Know someone who trades $ACRV? Share this with them.👇

Acrivon Therapeutics, Inc. Common Stock Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Acrivon Therapeutics, Inc. Common Stock. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Acrivon Therapeutics, Inc. Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Acrivon Therapeutics, Inc. Common Stock. The current macd is 0.06746975.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Acrivon price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Acrivon. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Acrivon price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Acrivon Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartAcrivon Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Acrivon Therapeutics, Inc. Common Stock. The current adx is 32.01.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Acrivon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Acrivon Therapeutics, Inc. Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Acrivon Therapeutics, Inc. Common Stock. The current sar is 1.38103756.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Acrivon Therapeutics, Inc. Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Acrivon Therapeutics, Inc. Common Stock. The current rsi is 56.54. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Acrivon Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) ChartAcrivon Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Acrivon Therapeutics, Inc. Common Stock. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acrivon price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Acrivon Therapeutics, Inc. Common Stock Daily Stochastic Oscillator ChartAcrivon Therapeutics, Inc. Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Acrivon Therapeutics, Inc. Common Stock. The current cci is 49.05.

Acrivon Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) ChartAcrivon Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Acrivon Therapeutics, Inc. Common Stock. The current cmo is 11.58.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Acrivon Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) ChartAcrivon Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Acrivon Therapeutics, Inc. Common Stock. The current willr is -83.94160584.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Acrivon Therapeutics, Inc. Common Stock Daily Williams %R ChartAcrivon Therapeutics, Inc. Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Acrivon Therapeutics, Inc. Common Stock.

Acrivon Therapeutics, Inc. Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Acrivon Therapeutics, Inc. Common Stock. The current atr is 0.16714407.

Acrivon Therapeutics, Inc. Common Stock Daily Average True Range (ATR) ChartAcrivon Therapeutics, Inc. Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Acrivon Therapeutics, Inc. Common Stock. The current obv is 70,601,082.

Acrivon Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) ChartAcrivon Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Acrivon Therapeutics, Inc. Common Stock. The current mfi is 90.86.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Acrivon Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) ChartAcrivon Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Acrivon Therapeutics, Inc. Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Acrivon Therapeutics, Inc. Common Stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Acrivon Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.536
Ma 20Greater thanMa 501.408
Ma 50Greater thanMa 1001.358
Ma 100Greater thanMa 2001.322
OpenGreater thanClose1.550
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Acrivon with someone you think should read this too:
  • Are you bullish or bearish on Acrivon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acrivon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Acrivon Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Acrivon Therapeutics, Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Acrivon Therapeutics, Inc. Common Stock.

Receive notifications about Acrivon Therapeutics, Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.